Trials / Unknown
UnknownNCT06250062
A Clinical Study of JS005 in Patients With Ankylosing Spondylitis
A Phase II, Randomized, Double-blind, Placebo-controlled , Multicenter Study to Evaluate the Preliminary Efficacy and Safety of Subcutaneous Injection of Recombinant Humanized Anti-IL-17A Monoclonal Antibody（JS005） in Adult Patients With Active Ankylosing Spondylitis
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 261 (estimated)
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd. · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicentre, randomized, double-blind, parallel, placebo-controlled Phase II clinical study of 261 adults with active ankylosing spondylitis to evaluate the efficacy and safety of JS005 in the treatment of active ankylosing spondylitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Recombinant humanized IL-17A Monoclonal Antibody（JS005） | Injection |
| DRUG | Placebo（JS005） | Injection |
Timeline
- Start date
- 2024-01-12
- Primary completion
- 2025-02-26
- Completion
- 2025-10-08
- First posted
- 2024-02-08
- Last updated
- 2024-02-08
Locations
38 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06250062. Inclusion in this directory is not an endorsement.